- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02908048
Extracellular RNA Markers of Liver Disease and Cancer
March 12, 2024 updated by: Tushar Patel, Mayo Clinic
The study will examine and evaluate the use of extracellular RNA in blood as markers for the diagnosis of liver disease or cancer, and as markers for prediction of response to treatment or recurrence of cancer after surgery
Study Overview
Status
Active, not recruiting
Intervention / Treatment
Detailed Description
The goal is to identify an extracellular RNA candidate for the detection and diagnosis of liver cancers such as hepatocellular cancer or biliary cancer, and chronic liver diseases.
The use of selected exRNA biomarkers for diagnosis of hepatocellular cancer (HCC) or biliary tract cancers in patients with cirrhosis will be evaluated in a prospective case-control study.
The study will create a registry of patients who have chronic liver disease, cirrhosis, liver and biliary tract cancers.
A risk factor questionnaire will be administered to facilitate identification of risk factors for development of liver cancer.
Patient information will be obtained from the medical record, and include demographics, medical history, liver disease, smoking and alcohol history, etiology, family history, and clinical laboratory data.
Study Type
Observational
Enrollment (Actual)
1810
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Florida
-
Jacksonville, Florida, United States, 32224
- Mayo Clinic Florida
-
-
Illinois
-
Chicago, Illinois, United States, 60637
- The University of Chicago Medical Center
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
Virginia
-
Richmond, Virginia, United States, 23249
- McGuire VA Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Sampling Method
Non-Probability Sample
Study Population
Patients undergoing evaluation at Mayo Clinic Florida Liver Transplant, Surgery, Oncology or Radiology clinics who have hepatocellular carcinoma (HCC) or biliary tract cancers, cirrhosis without HCC, or chronic liver disease without cirrhosis.
Description
Inclusion Criteria:
- Lab results from within the previous 90 days.
- Diagnosis of HCC or biliary tract cancer
- Diagnosis of cirrhosis based on histology, imaging, or ultrasound.
- Diagnosis of a chronic liver disease without cirrhosis.
Exclusion Criteria for the HCC/biliary tract cancer group:
- Prior solid organ transplant.
- Previous cancer history with the last 5 years (excluding non-melanoma skin cancer), participation in a treatment trial for HCC
Exclusion criteria for the cirrhosis and chronic liver disease groups:
- Prior solid organ transplant.
- Previous or current cancer history within the past 5 years (excluding non-melanoma skin cancer).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Hepatocellular Carcinoma
Blood samples will be collected at entry into the study and at varying intervals over a two to three year period.
|
Blood samples collected at varying intervals over a two to three year period.
|
Biliary Tract Cancer
Blood samples will be collected at entry into the system and at varying intervals over a two to three year period.
|
Blood samples collected at varying intervals over a two to three year period.
|
Cirrhosis
Blood samples will be collected during regular intervals over a three year period.
|
Blood samples collected at varying intervals over a two to three year period.
|
Chronic Liver Disease without Cirrhosis
A single blood sample will be collected at entry into the study
|
Blood samples collected at varying intervals over a two to three year period.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Diagnosis of liver cancer based on tumor markers and imaging studies.
Time Frame: Five years
|
The exRNA biomarker levels in the HCC and biliary tract cancer groups will be evaluated and compared to the exRNA biomarker levels present in the case-control groups, cirrhosis and chronic liver disease.
Statistical analysis will be used to evaluate the sensitivity and specificity of these markers for the diagnosis of cancers based on findings of liver mass, imaging characteristics, size, and extent of viable tumor on imaging, or on elevated levels of tumor markers such as alphafetoprotein.
|
Five years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Tushar Patel, MBChB, Mayo Clinic
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2014
Primary Completion (Estimated)
July 1, 2026
Study Completion (Estimated)
July 1, 2026
Study Registration Dates
First Submitted
September 14, 2016
First Submitted That Met QC Criteria
September 16, 2016
First Posted (Estimated)
September 20, 2016
Study Record Updates
Last Update Posted (Actual)
March 13, 2024
Last Update Submitted That Met QC Criteria
March 12, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Digestive System Neoplasms
- Liver Neoplasms
- Biliary Tract Diseases
- Liver Diseases
- Fibrosis
- Carcinoma
- Carcinoma, Hepatocellular
- Biliary Tract Neoplasms
Other Study ID Numbers
- 14-004560
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Liver Diseases
-
King's College Hospital NHS TrustSamsung MedisonRecruitingHepatitis | Liver Fat | NAFLD | Fibrosis, Liver | Liver Disease Chronic | Liver Steatoses | NASH With FibrosisUnited Kingdom
-
Beijing Chao Yang HospitalUnknownLiver Transplantation | End Stage Liver DIseaseChina
-
Beijing Friendship HospitalUnknownNonalcoholic Fatty Liver Disease | Liver Steatosis | Liver FibrosisChina
-
Shiraz University of Medical SciencesCompletedFatty Liver | Fatty Liver, NonalcoholicIran, Islamic Republic of
-
Institute of Liver and Biliary Sciences, IndiaCompletedAcute Liver FailureIndia
-
Medical College of WisconsinRecruiting
-
HaEmek Medical Center, IsraelTerminatedPatients With Fatty Liver DiseaseIsrael
-
Beijing Continent Pharmaceutical Co, Ltd.RecruitingAcute-On-Chronic Liver Failure | Acute Liver FailureChina
-
Taipei City HospitalThe One Biopharmaceutical Co., Ltd.CompletedNon-alcoholic Fatty Liver Disease | Liver Fibrosis | Liver InjuryTaiwan
-
Chuncheon Sacred Heart HospitalSuspendedChronic Liver Disease | Acute Derangement of Liver FunctionKorea, Republic of
Clinical Trials on Blood samples
-
Assistance Publique Hopitaux De MarseilleCompleted
-
Centre Hospitalier Universitaire DijonCompletedPrimary Immune Thrombocytopenia (ITP)France
-
Institut BergoniéUnknown
-
Gustave Roussy, Cancer Campus, Grand ParisUnknownPaediatric MalignanciesFrance
-
Centre Georges Francois LeclercCompleted
-
Centre Hospitalier Universitaire de NīmesCompletedHenoch Schönlein PurpuraFrance
-
Centre Hospitalier Universitaire DijonCompleted
-
Assistance Publique Hopitaux De MarseilleRecruitingPlastic SurgeriesFrance
-
University Hospital, BordeauxRecruitingSystemic Sclerosis | SclerodermaFrance
-
Centre Hospitalier Universitaire, AmiensCompleted